Acadia Pharma down 17% premarket on Nuplazid safety concerns https://seekingalpha.com/news/3344387-acadia-pharma-17-percent-premarket-nuplazid-safety-concerns
Shares of Acadia Pharmaceuticals Inc. ACAD, +58.28% rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint.